%PDF-1.4
%
19 0 obj
<>
endobj
16 0 obj
<>
endobj
68 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T14:19:36Z
2024-03-29T06:35:03-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-29T06:35:03-07:00
application/pdf
Heather
2002-646.april
uuid:259c4f1d-1dd2-11b2-0a00-4f0827fd5800
uuid:259c4f20-1dd2-11b2-0a00-6a0000000000
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
74 0 obj
[78 0 R]
endobj
75 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.1958 Tw 10 0 0 10 54 713.1616 Tm
(dextrose may increase urate excretion due to an osmotic)Tj
-0.00031 Tc 0 Tw 0 -1.2 TD
[(ef)17.5 (fect)]TJ
0 Tc 6.5 0 0 6.5 76.5708 704.4616 Tm
(6)Tj
-0.00011 Tc 0.0014 Tw 10 0 0 10 79.8208 701.1616 Tm
(. Other potential causes of uricosuria such as glycine-)Tj
0.33881 Tw -2.5821 -1.2 Td
(rich amino acid solutions \(17\32025 g/day\))Tj
0 Tc 0 Tw 6.5 0 0 6.5 230.6188 692.4616 Tm
(3,6,7)Tj
0.3387 Tw 10 0 0 10 243.6187 689.1616 Tm
(, high dose)Tj
-0.00011 Tc 0.1933 Tw -18.9619 -1.2 Td
(ascorbic acid \(4 g/day\), and elevated blood sugars)Tj
0 Tc 0 Tw 6.5 0 0 6.5 267.4403 680.4615 Tm
(6)Tj
-0.00011 Tc 10 0 0 10 275.1233 677.1616 Tm
(have)Tj
0.0923 Tw -22.1123 -1.2 Td
[(been reported as a possible etiology)64.8 (, but not substantiated.)]TJ
0.03661 Tw T*
(Extracellular fluid expansion possibly due to stimulation of)Tj
0.02499 Tw T*
(antidiuretic hormone has been postulated)Tj
0 Tw 6.5 0 0 6.5 219.3848 644.4615 Tm
(5-7)Tj
0 Tc 10 0 0 10 228.0477 641.1616 Tm
(.)Tj
-0.00011 Tc 0.1812 Tw -16.2048 -1.2 Td
[(Evaluation of the )17.8 (TPN formula in this case found the)]TJ
0.16071 Tw -1.2 -1.2 Td
(patient was receiving an amino acid infusion of 0.75\3201.5)Tj
0.0909 Tw T*
(g/kg/day and dextrose infusion rate up to 2.85 mg/kg/min.)Tj
-0.0275 Tw T*
[(In each course of )17.7 (TPN, the patient was started at a lower rate)]TJ
0.35381 Tw T*
[(and titrated to the maximum rates noted. )17.7 (The glycine)]TJ
0.0685 Tw T*
[(content of each day\325)54.8 (s )17.7 (TPN solution was roughly 0.5 g/day)64.9 (,)]TJ
0.37241 Tw T*
(much lower than the amounts noted to be uricosuric.)Tj
0.0965 Tw T*
[(Unfortunately)64.8 (, we did not measure urinary uric acid clear-)]TJ
0.0603 Tw T*
(ance or fractional excretion of urate to assess for increased)Tj
0.1801 Tw T*
(urinary clearance. Standard injectable multivitamins were)Tj
0.02499 Tw T*
(used daily and contained only 100 mg ascorbic acid.)Tj
0.11301 Tw 1.2 -1.2 Td
[(For patients with or at risk for gout, feeding with )17.7 (TPN)]TJ
-0.03169 Tw -1.2 -1.2 Td
[(becomes a dif)17.7 (ficult issue. )17.7 (There are no current guidelines for)]TJ
0.0723 Tw T*
[(formulating )17.7 (TPN solutions in this population and very few)]TJ
0.07201 Tw T*
[(data exist. )17.7 (There is no indication that using lower doses of)]TJ
0.0199 Tc 0.4756 Tw T*
(amino acid or dextrose will prevent hypouricemia.)Tj
-0.00011 Tc 0 Tw T*
[(W)39.9 (idhalm, )]TJ
/T1_1 1 Tf
0.058 Tw 4.2395 0 Td
(et al)Tj
/T1_0 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 114.4706 440.4616 Tm
(8)Tj
-0.00011 Tc 0.05811 Tw 10 0 0 10 120.8013 437.1616 Tm
(showed that a lipid emulsion based on soy)Tj
0.1945 Tw -6.6801 -1.2 Td
[(oil \(20%\) had no ef)17.7 (fect on uric acid concentrations, and)]TJ
0.0554 Tw T*
[(therefore it may be feasible to use lipid-rich )17.7 (TPN solutions)]TJ
0.02499 Tw T*
(in this population.)Tj
0.1113 Tw 1.2 -1.2 Td
(Routine daily monitoring of uric acid concentrations in)Tj
0.0939 Tw -1.2 -1.2 Td
(addition to standard biochemical measurements in patients)Tj
0.20129 Tw 26.4 33.6 Td
(with gout may be helpful to alert clinicians to declining)Tj
0.0498 Tw T*
(serum levels and potential exacerbations of gout in suscep-)Tj
-0.00191 Tw T*
[(tible patients. It is feasible that this patient\325)54.9 (s serum uric acid)]TJ
0.0258 Tw T*
(diminished as a result of an acute episode of gout, although)Tj
-0.0276 Tw T*
[(no other definite risk factors were temporally identified. )17.7 (The)]TJ
0.0199 Tc 0.5869 Tw T*
(role of prophylactic or therapeutic corticosteroids,)Tj
-0.00011 Tc 0.15421 Tw T*
(colchicine, or nonsteroidal antiinflammatory drugs and of)Tj
0.0029 Tw T*
[(their route of administration is less clear)54.8 (. )17.7 (The potential toxi-)]TJ
0.0201 Tw T*
[(cities of preventive therapy need to be considered carefully)64.8 (.)]TJ
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 583.1616 Tm
[(1.)-875.1 (W)79.9 (ortman RI, Kelley )17.7 (WN. Crystal-associated synovitis. In: Ruddy S,)]TJ
1.675 -1.25 Td
[(Harris ED, Sledge CB, editors. Kelley\325)54.8 (s textbook of rheumatology)64.8 (.)]TJ
0 -1.25 TD
[(V)128.9 (ol. 2. Philadelphia: )17.7 (WB Saunders; 2001:1365.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Gurwitz JH, Kalish SC, Bohn RI, et al. )17.7 (Thiazide diuretics and the)]TJ
1.675 -1.25 Td
[(initiation of anti-gout therapy)64.8 (. J Clin Epidemiol 1997;50:953-9.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Al-Jurf )54.8 (A, Steiger E. Hypouricemia in total parenteral nutrition. )54.8 (Am)]TJ
1.675 -1.25 Td
(J Clin Nutr 1980;33:2630-4.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Koretz RL. Hypouricemia \321 a transient biochemical phenomenon)]TJ
1.675 -1.25 Td
[(of total parenteral nutrition. )54.8 (Am J Clin Nutr 1981;34:2493-8.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Morichau-Beauchant M, Beau P)110.7 (, Druart F)79.7 (, Matuchansky C. Ef)17.7 (fects)]TJ
1.675 -1.25 Td
(of prolonged, purine-free total parenteral and enteral nutrition on)Tj
T*
[(urate homeostasis in man. )54.8 (Am J Clin Nutr 1982;35:997-1002.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Derus CL, Levinson DJ, Bowman B, et al. )54.8 (Altered fractional )]TJ
1.675 -1.25 Td
(excretion of uric-acid during total parenteral nutrition. J Rheumatol)Tj
0 Tc 0 Tw T*
(1987;14:978-81.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Batuman )17.7 (V)128.9 (, Dreisbach )54.8 (A, Maesaka JK, Rothkopf M, Ross E. Renal)]TJ
1.675 -1.25 Td
[(and electrolyte ef)17.7 (fects of total parenteral nutrition. JPEN J Parenter)]TJ
T*
(Enteral Nutr 1984;8:546-51.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (W)39.8 (idhalm K, Kohl S, Hammerle )54.8 (A. )17.7 (The clinical application of two)]TJ
1.675 -1.25 Td
(newly developed lipid emulsions \(Solipid 20% S&E\) in critically ill)Tj
T*
[(patients. Infusionsther )17.7 (T)35 (ransfusionsmed 1996;23:8-12.)]TJ
ET
0 0 0 0 scn
420 777 137 -27 re
f*
BT
0 0 0 1 scn
/T1_3 1 Tf
0 Tw 20.37 0 0 21 460.9631 760.6089 Tm
(\002\003\003\002\004\005\006\005\004\002)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(850)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
25 0 obj
<>
endobj
23 0 obj
<>
endobj
35 0 obj
<>
endobj
24 0 obj
<>
endobj
63 0 obj
<>
endobj
73 0 obj
<>
endobj
29 0 obj
<>
endobj
31 0 obj
<>
endobj
27 0 obj
<>stream
H\OO@|=jNi^P;%MYooxf{d44;LŐ4Sfχ.M$hxuv0"{_e^O]n߆{m8u`s6vq